Strand, Vibeke
Lee, Eun Bong
Yazici, Yusuf
Dikranian, Ara
Wilkinson, Bethanie
Takiya, Liza
Zang, Chuanbo
Bananis, Eustratios
Bergman, Martin J.
Funding for this research was provided by:
Pfizer Inc
Article History
Received: 7 February 2018
Revised: 14 March 2018
Accepted: 21 March 2018
First Online: 14 April 2018
Compliance with ethical standards
:
: V Strand has received consulting fees from AbbVie, Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Celltrion, Genentech/Roche, GSK, Janssen, Lilly, Merck, Novartis, Pfizer Inc, Regeneron, Samsung, Sandoz, Sanofi, and UCB. EB Lee has received consulting fees from Pfizer Inc. Y Yazici has received research grants and consulting fees from BMS, Celgene, and Genentech. A Dikranian is a member of the speaker’s bureau for AbbVie, Amgen, BMS, Celgene, Genentech, Mallinckrodt, Pfizer Inc, Regeneron, and Sanofi Genzyme and has received consulting fees from Pfizer Inc, Regeneron, and Sanofi Genzyme. B Wilkinson, L Takiya, C Zang, and E Bananis are employees and shareholders of Pfizer Inc. MJ Bergman has received consulting fees from AbbVie, Amgen, BMS, Celgene, Genentech, Janssen, Novartis, and Pfizer Inc; is a member of the speaker’s bureau for AbbVie, Celgene, and Novartis; and owns stocks in Merck and Pfizer Inc.
: Both RCTs were conducted in accordance with the Declaration of Helsinki, International Conference on Harmonisation Guidelines for Good Clinical Practice and local country regulations. The trial protocols were approved by the Institutional Review Boards and/or Independent Ethics Committee at each trial center. All patients provided written, informed consent.